Search

Displaying results 5721 - 5730 of 10000 in total
  1. Drug

    ALTU-135

    go.drugbank.com/drugs/DB05330
    Investigational

    ALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA). … This consistent and pure enzyme combination is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals.

  2. Drug

    PG-530742

    go.drugbank.com/drugs/DB05495
    Investigational

    Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis. … PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis.

  3. Drug

    N(4)-Adenosyl-N(4)-methyl-2,4-diaminobutanoic acid

    go.drugbank.com/drugs/DB03458
    Experimental

    This compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar.

  4. Drug

    Rocatinlimab

    go.drugbank.com/drugs/DB18809
    Investigational

    The drug works by targeting the OX40 receptor, which plays a role in the immune response associated with atopic dermatitis. … Rocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe atopic dermatitis.

  5. Drug

    Cortisone

    go.drugbank.com/drugs/DB14681
    Investigational

    It is converted in the liver to the active metabolite hydrocortisone. (From Martindale, The Extra Pharmacopoeia, 30th ed, p726)

    Synonyms: Kendall's compound ECategories: Corticosteroid Hormone Receptor Agonists
  6. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. … The Company determined that the program was not meeting their expected primary and exploratory objectives.

  7. Drug

    Asoprisnil

    go.drugbank.com/drugs/DB06680
    Investigational

    Asoprisnil (J867) is a selective progesterone receptor modulator. It can be used to treat progesterone sensitive myomata.

  8. Drug

    Benfotiamine

    go.drugbank.com/drugs/DB11748
    ApprovedInvestigationalWithdrawn

    Benfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2.

  9. Drug

    Mannitol busulfan

    go.drugbank.com/drugs/DB12097
    ApprovedWithdrawn

    Mm has been used in trials studying the treatment of Cocaine Dependence and Diabetes Mellitus, Type 2.

  10. Drug

    Boscalid

    go.drugbank.com/drugs/DB12792
    ApprovedWithdrawn

    Boscalid has been investigated for the treatment of OSDI, Glaucoma, Staining, Schirmers, and Disease Severity, among others.